{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T18:38:20Z","timestamp":1784140700159,"version":"3.55.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012505","name":"Hebei Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012505","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.jchromb.2023.123680","type":"journal-article","created":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T19:41:29Z","timestamp":1679341289000},"page":"123680","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Quantification of orelabrutinib in human plasma and cerebrospinal fluid by liquid chromatography tandem mass spectrometry"],"prefix":"10.1016","volume":"1221","author":[{"given":"Shengnan","family":"Ji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianfeng","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2015","key":"10.1016\/j.jchromb.2023.123680_b0005","first-page":"E359","article-title":"Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN","volume":"136","author":"Ferlay","year":"2012","journal-title":"Int. J. Cancer."},{"key":"10.1016\/j.jchromb.2023.123680_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109235","article-title":"Tumor-associated macrophages in lymphoma: From mechanisms to therapy","volume":"112","author":"Xiong","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.jchromb.2023.123680_b0015","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1038\/bjc.2015.94","article-title":"Lymphoma incidence, survival and prevalence 2004\u20132014: sub-type analyses from the UK\u2019s Haematological Malignancy Research Network","volume":"112","author":"Smith","year":"2015","journal-title":"Br. J. Cancer."},{"key":"10.1016\/j.jchromb.2023.123680_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114232","article-title":"Recent development of BTK-based dual inhibitors in the treatment of cancers","volume":"233","author":"Ran","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jchromb.2023.123680_b0025","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton\u2019s tyrosine kinase in B cells and malignancies","volume":"17","author":"Pal Singh","year":"2018","journal-title":"Mol. Cancer."},{"key":"10.1016\/j.jchromb.2023.123680_b0030","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41375-020-01072-6","article-title":"Inhibitors targeting Bruton\u2019s tyrosine kinase in cancers: drug development advances","volume":"35","author":"Wen","year":"2021","journal-title":"Leukemia."},{"key":"10.1016\/j.jchromb.2023.123680_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113329","article-title":"Emerging small-molecule inhibitors of the Bruton\u2019s tyrosine kinase (BTK): Current development","volume":"217","author":"Liu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jchromb.2023.123680_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116358","article-title":"Progress in the development of small molecular inhibitors of the Bruton\u2019s tyrosine kinase (BTK) as a promising cancer therapy","volume":"47","author":"Liu","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.jchromb.2023.123680_b0045","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1182\/blood-2021-144691","article-title":"Orelabrutinib, a Selective Bruton\u2019s Tyrosine Kinase (BTK) Inhibitor in the Treatment of Primary Immune Thrombocytopenia (ITP)","volume":"138","author":"Yu","year":"2021","journal-title":"Blood."},{"key":"10.1016\/j.jchromb.2023.123680_b0050","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ejmech.2016.11.047","article-title":"Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton\u2019s tyrosine kinase (BTK) inhibitors with improved activity toward B leukemia cell lines","volume":"126","author":"Zhao","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jchromb.2023.123680_b0055","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/PPO.0000000000000412","article-title":"Bruton tyrosine kinase inhibitors: present and future","volume":"25","author":"Burger","year":"2019","journal-title":"Cancer J."},{"key":"10.1016\/j.jchromb.2023.123680_b0060","doi-asserted-by":"crossref","first-page":"7641","DOI":"10.3390\/ijms22147641","article-title":"Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective","volume":"22","author":"Brullo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jchromb.2023.123680_b0065","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/s41419-019-2158-0","article-title":"Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K\/AKT activation in B-cell lymphoid malignancies","volume":"10","author":"Kapoor","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.jchromb.2023.123680_b0070","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: up to 6 years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.jchromb.2023.123680_b0075","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2217\/fon-2019-0844","article-title":"ALPINE: zanubrutinib versus ibrutinib in relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"16","author":"Hillmen","year":"2020","journal-title":"Future Oncol."},{"key":"10.1016\/j.jchromb.2023.123680_b0080","article-title":"Does the use of the Bruton Tyrosine Kinase inhibitors and the c-kit inhibitor masitinib result in clinically significant outcomes among patients with various forms of multiple sclerosis?","volume":"67","author":"Arsenault","year":"2022","journal-title":"Mult Scler Relat. Dis."},{"key":"10.1016\/j.jchromb.2023.123680_b0085","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood-2020-140172","article-title":"Pooled Analysis of Safety Data from Clinical Trials of Orelabrutinib Monotherapy in Hematologic Malignancies","volume":"136","author":"Song","year":"2020","journal-title":"Blood."},{"key":"10.1016\/j.jchromb.2023.123680_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2022.114964","article-title":"A UPLC-MS\/MS method for simultaneous determination of eight special-grade antimicrobials in human plasma and application in TDM","volume":"220","author":"Qi","year":"2022","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2023.123680_b0095","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.forsciint.2013.02.010","article-title":"LC\u2013MS\/MS of some atypical antipsychotics in human plasma, serum, oral fluid and haemolysed whole blood","volume":"229","author":"Fisher","year":"2013","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.jchromb.2023.123680_b0100","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2377-5-22","article-title":"A chronic fatigue syndrome \u2013 related proteome in human cerebrospinal fluid","volume":"5","author":"Baraniuk","year":"2005","journal-title":"BMC Neurology."},{"key":"10.1016\/j.jchromb.2023.123680_b0105","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1007\/s00216-020-02403-3","article-title":"Investigating surrogate cerebrospinal fluid matrix compositions for use in quantitative LC-MS analysis of therapeutic antibodies in the cerebrospinal fluid","volume":"412","author":"Fogh","year":"2020","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jchromb.2023.123680_b0110","article-title":"Mechanisms of fluid movement into, through and out of the brain: evaluation of the evidence","volume":"11. 26","author":"Hladky","year":"2014","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.jchromb.2023.123680_b0115","first-page":"84","volume":"L180","author":"Commission","year":"2021","journal-title":"OJ."},{"key":"10.1016\/j.jchromb.2023.123680_b0120","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.chroma.2007.01.018","article-title":"Matrix-induced response enhancement in pesticide residue analysis by gas chromatography","volume":"1158","author":"Poole","year":"2007","journal-title":"J. Chromatogr. A."},{"key":"10.1016\/j.jchromb.2023.123680_b0125","article-title":"Evaluation of the matrix effect in the quantitative bio-oil analysis by gas chromatography","volume":"290","author":"Lazzari","year":"2020","journal-title":"Fuel."},{"key":"10.1016\/j.jchromb.2023.123680_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.microc.2021.106375","article-title":"Evaluation of the matrix effect of pH value and sugar content on the analysis of pesticides in tropical fruits by UPLC-MS\/MS","volume":"168","author":"Zhao","year":"2021","journal-title":"Microchem. J."}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023223000909?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023223000909?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T23:10:19Z","timestamp":1761606619000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023223000909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":26,"alternative-id":["S1570023223000909"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2023.123680","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantification of orelabrutinib in human plasma and cerebrospinal fluid by liquid chromatography tandem mass spectrometry","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2023.123680","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"123680"}}